1. GrosserT, FriesS, FitzGeraldGA (2006) Biological basis for the cardiovascular consequences of Cox 2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4–15.
2. HenryD, LimL, Garcia RodriguezL, Perez GutthannS, CarsonJL, et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312: 1563–1566.
3. Masso GonzalezE, PatrignaniP, TacconelliS, Garcia RodriguezL (2010) Variability among non-steroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. Arth Rheum 62: 1592–1601.
4. Hernandez-DıazS, Varas-Lorenzo, Garcıa RodrıguezL (2006) Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266–274.
5. SinghS, WuO, LanghorneP, MadhokR (2006) Risk of acute myocardial infarction with non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 8: R153.
6. McGettiganP, HenryD (2006) Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective anad non-selective inhibitors of cyclo-oxygenase. JAMA 296: 1633–1644.
7. TrelleS, ReichenbachS, WandelS, HildebrandP, TschannenB, et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: a network meta-analysis. BMJ 342: c7086.
8. KearneyP, BaigentC, GoodwinJ, HallsH, EmbersonJ, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308.
9. McGettiganP, HenryD (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098 doi:10.1371/journal.pmed.1001098.
10. ScheimanJM, HindleyCE (2010) Strategies to optimise treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32: 667–677.
11. RostomA, MuirK, DubeC, LanasA, JolicoeurE, TugwellP (2009) Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and cox-2 inhibitors. Drug Healthcare Patient Safety 1: 47–71.
12. StrandV (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370: 2138–51.
13. Garcia RodriguezL, TacconelliS, PatrignaniP (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52: 1628–1636.
14. DansA, NgN, VargheseC, TaiES, FirestoneR, et al. (2011) The rise of chronic non-communicable diseases in Southeast Asia: time for action. Lancet 337: 680–89.
15. World Health Organization (2011) WHO model list of essential medicines 17th List March 2011. Available: http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf. Accessed 12 September 2012.
16. World Health Organization (2012) Essential medicines selection. Available: http://www.who.int/selection_medicines/country_lists/en/index.html. Accessed 12 September 2012.
17. World Health Organization (2010) Fact sheet number 325. Medicines: essential medicines. Available: http://www.who.int/mediacentre/factsheets/fs325/en/index.html. Accessed 4 November 2012.
18. World Health Organization (2012) ATC/DDD Index 2012. Available: http://www.whocc.no/atc_ddd_index/. Accessed 12 September 2012.
19. NHS (2011) Prescription cost analysis England 2011. Available: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england-2011. Accessed 12 November 2012.
20. Merck (2004) Merck announces voluntary worldwide withdrawal of Vioxx. Available: http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf. Accessed 12 September 2012.
21. FosbolEL, FolkeF, JacobsenS, RasmussenJN, SørensenR, et al. (2010) Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 3: 395–405.
22. CannonCP, CurtisSP, FitzGeraldGA, KrumH, KaurA, BologneseJA, et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781.
23. World Health Organization (2012) NCD mortality 2008. Available: http://gamapserver.who.int/gho/interactive_charts/ncd/mortality/cvd/atlas.html. Accessed 12 September 2012.
24. DeeksJJ, SmithLA, BradleyMD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for the treatment of osteoarthritis and rheumatoid arthritis: a systematic review of randomised controlled trials. BMJ 325: 619–623.
25. CollinsSL, MooreRA, McQuayHJ, WiffenPJ (1998) Oral ibuprofen and diclofenac in post-operative pain: a quantitative systematic review. Eur J Pain 2: 285–291.
26. European Medicines Agency (2012) Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk: outcome of a procedure under Article 5(3) of Regulation (EC) No 726/20041. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001637.jsp&mid=WC0b01ac058004d5c1. Accessed 11 November 2012.